Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY) saw unusually-high trading volume on Friday . Approximately 122,304 shares were traded during trading, an increase of 127% from the previous session’s volume of 53,801 shares.The stock last traded at $15.20 and had previously closed at $15.21.

Analyst Ratings Changes

FSNUY has been the subject of a number of research reports. Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Fresenius SE & Co. has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

The stock has a 50-day moving average of $14.60 and a two-hundred day moving average of $14.43. The firm has a market cap of $34.02 billion, a price-to-earnings ratio of 23.97 and a beta of 0.75. The company has a current ratio of 1.26, a quick ratio of 0.99 and a debt-to-equity ratio of 0.49.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. Fresenius SE & Co. had a return on equity of 10.38% and a net margin of 5.71%.The firm had revenue of $6.94 billion for the quarter. On average, analysts anticipate that Fresenius SE & Co. will post 0.79 EPS for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.